Currax 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
28 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Contrave (naltrexone/bupropion) / Currax
2021-002145-15: Using Mysimba, weight loss medication, in patients who previously underwent a stomach altering operation, because of being extremely overweight, and are now regaining weight again.

Not yet recruiting
4
116
Europe
naltrexone/bupropion, Tablet, Mysimba 8 mg/90 mg prolonged-release tablets
Nederlandse Obesitas Kliniek, Goodlife
Weight regain post bariatric surgery, Weight regain after stomach altering weight loss surgery because of being overweight, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
 
 
COR-WR, NCT04587843: A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery

Active, not recruiting
4
18
Canada
Contrave 8Mg-90Mg Extended-Release Tablet, naltrexone HCl/bupropion HCl, Placebo, Inactive
St. Joseph's Healthcare Hamilton, Bausch Health, Canada Inc.
Obesity
12/23
12/23
COR-WM, NCT04589130: Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.

Active, not recruiting
4
89
Canada
Contrave 8Mg-90Mg Extended-Release Tablet, naltrexone HCl/bupropion HCl, Placebo, Inactive
St. Joseph's Healthcare Hamilton, Bausch Health, Canada Inc.
Obesity
12/23
12/23
NCT06809166: Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity

Recruiting
4
40
Canada
Contrave, Naltrexone/Bupropion-NB, Placebo, Vitamin Pill, Diet Program
The Royal's Institute of Mental Health Research, University of Ottawa, The Royal Ottawa Mental Health Centre, Bausch Health, Canada Inc., CHEO Research Institute, LEAF Weight Management Clinic
Obesity, Weight Loss, Weight Management, Dietary Intervention, Obesity/Therapy
06/25
07/25
NCT05579249: A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Completed
4
500
US
Semaglutide, Wegovy, Orlistat, Xenical, Phentermine/Topiramate, Qsymia, Naltrexone/Bupropion, Contrave, Liraglutide, Saxenda
Novo Nordisk A/S
Obesity
11/24
11/24
NCT04902625: Use of Mysimba in Patients With Weight Regain After Bariatric Surgery

Recruiting
4
116
Europe
Naltrexone-Bupropion Combination, Mysimba, Contrave
Zuyderland Medisch Centrum, Nederlandse Obesitas Kliniek
Obesity, Morbid, Bariatric Surgery Candidate, Medication Persistence
03/25
03/25
MEDFAST, NCT06845345: The Effect of Diet or Medication to Lose Weight in People with Type 2 Diabetes and Liver Scarring

Recruiting
4
70
Europe
early time restricted Mediterranean diet, early time restricted eating, mediterranean diet, intermittent fasting, dietary intervention, Mysimba, naltrexone/bupropion, pharmacological intervention
Carmen Dietvorst
Diabetes Mellitus, Type 2, Liver Fibrosis, Liver Steatoses, Hepatic Steatosis, Hepatic Fibrosis, Overweight or Obesity
07/26
03/27
STAY-LEAN, NCT06854614: Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial ( Trial)

Recruiting
4
150
US
Comprehensive weight loss, Enhanced lifestyle changes, Phentermine-Topiramate, Qsymia, Naltrexone-Bupropion Combination, Contrave, Orlistat, Xenical
The Cleveland Clinic
Obesity
12/25
12/26
NCT05919797: Weight Loss Study: Genetics and Response to Naltrexone/Bupropion

Recruiting
4
120
US
Naltrexone-Bupropion Combination, Contrave
Columbia University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Obesity
06/27
06/27
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting
4
8600
US
Naltrexone-Bupropion (NB) Combination, Placebo
Currax Pharmaceuticals
Obesity
01/29
07/29
NCT03045341: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

Completed
2/3
136
US
NB medication (Naltrexone Bupropion combination), Contrave, Behavioral Weight Loss (BWL) counseling, Placebo
Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Binge-eating Disorder, Obesity
07/21
12/22
NCT03063606: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment

Completed
2/3
31
US
Cognitive-Behavioral Therapy (CBT), NB Medication (on-going from acute treatment), Contrave
Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Binge-Eating Disorder, Obesity
12/21
12/22
NCT03047005: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy

Completed
2/3
68
US
NB medication (Naltrexone Bupropion combination), Contrave, Placebo
Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Binge-Eating Disorder, Obesity
12/21
12/22
NCT03539900: Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

Completed
2/3
89
US
Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination, Contrave, Placebo
Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Binge-Eating Disorder
04/22
03/23
NCT04599478: Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)

Recruiting
2/3
160
US
Naltrexone and Bupropion medication, Contrave, Behavioral Weight Loss, Placebo
Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Loss-of-control Eating, Obesity/Overweight
01/26
01/27
NCT04605081: Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)

Enrolling by invitation
2/3
100
US
Naltrexone and Bupropion (NB) medication, Contrave, Placebo
Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Loss-of-Control Eating, Obesity/Overweight
05/27
05/27
A-NEW, NCT04499950: Adaptive Nutrition and Exercise Weight Loss () Study

Completed
2
53
US
Contrave, Naltrexone/Bupropion, Behavioral Weight Loss
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, American Institute for Cancer Research, Breast Cancer Research Foundation, Hopkins-WellSpan Cancer Research Fund
Breast Cancer, Overweight or Obesity
01/24
01/24
NCT04553263: Relapse Prevention in Stimulant Use Disorder

Withdrawn
1
60
US
Contrave 8Mg-90Mg Extended-Release Tablet, Naltrexone HCl/Bupropion HCl 8 Mg-90 Mg, Bupropion, Wellbutrin, Zyban
University of California, Los Angeles
Stimulant Use, Relapse, Cognitive Function, ADHD
01/25
01/25
DUS, NCT06089824: Drug Utilisation of Mysimba/Contrave

Completed
N/A
43324
US
Currax Pharmaceuticals
Obesity
10/22
10/22
HOA, NCT06090461: Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

Completed
N/A
31889
US
Currax Pharmaceuticals
Obesity
12/22
12/22
NCT05756764: Anti-obesity Pharmacotherapy and Inflammation

Active, not recruiting
N/A
30
US
Semaglutide, Glucagon-like peptide-1 receptor (GLP1-R) agonist, Wegovy, Phentermine-Topiramate combination, Qsymia, Phentermine, Lomaira, Adipex-P, Tirzepatide, Mounjaro, Zepbound, GIP/GLP-1 RA, Topiramate, Topamax, Trokendi XR, Qudexy XR, Diethylpropion, Tenuate, Diethylcathinone, Naltrexone/Bupropion, Contrave, Liraglutide, Saxenda, Victoza
Louisiana State University Health Sciences Center in New Orleans, Tulane University, Pennington Biomedical Research Center, Ochsner Health System
Obesity
06/25
07/25
Cedax (ceftibuten dihydrate) / Currax
2016-003704-31: Impact on the intestinal flora during antibiotic treatment Påverkan av tarmens normalflora i samband med antibiotikabehandling

Not yet recruiting
2
120
Europe
Ciprofloxacin, Ceftibuten, Pivmecillinam, Nitrofurantoin, trimetoprim-sulfametoxazol, Coated tablet, Ciprofloxacin, Cedax, Selexid, Furadantin, Eusaprim forte
Uppsala University, Uppsala University
Impact on the intestinal microbiota during antibiotic treatment Påverkan av tarmens normalflora i samband med antibiotikabehandling, Impact on the intestinal flora during antibiotic treatment Påverkan av tarmens normalflora i samband med antibiotikabehandling, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT05554237: A Study to Learn About the Study Medicine Called CTB+AVP in Healthy Adult People.

Completed
1
42
Europe
Placebo, Placebo comparator, PF-07612577, CTB+AVP, PF-06264006, ceftibuten (CTB)
Pfizer
Healthy
06/23
06/23
NCT06593054: To Learn How Different Forms of Study Medicine Are Taken up Into the Blood and the Effect of Food on Study Medicine in Healthy Adults

Completed
1
13
Europe
Ceftibuten, Avibactam prodrug, CTB-AVP in Tablet
Pfizer
Healthy
10/24
10/24
NCT06079775: P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants

Recruiting
1
71
RoW
Xeruborbactam Oral Prodrug, QPX7831, Ceftibuten, Xeruborbactam Oral Prodrug Placebo, QPX7831 Placebo, Ceftibuten Placebo
Qpex Biopharma, Inc., Shionogi Inc., Biomedical Advanced Research and Development Authority
Bacterial Infections
08/25
10/25
NCT06665555: Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age

Completed
1
34
US
ledaborbactam etzadroxil, ceftibuten
Venatorx Pharmaceuticals, Inc., National Institute of Allergy and Infectious Diseases (NIAID)
Pharmacokinetics, Healthy Volunteers
03/25
03/25
NCT06157242: PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment

Completed
1
32
US
Xeruborbactam Oral Prodrug, QPX7831, Ceftibuten
Qpex Biopharma, Inc., Shionogi Inc., Biomedical Advanced Research and Development Authority
Bacterial Infections
03/25
03/25
VNRX-7145-106, NCT06733675: Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

Active, not recruiting
1
46
US
Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil, Esomeprazole
Venatorx Pharmaceuticals, Inc., Biomedical Advanced Research and Development Authority
Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI), FDC
08/25
09/25
Rezira (hydrocodone bitartrate/pseudoephedrine) / Currax
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Contrave (naltrexone/bupropion) / Currax
2021-002145-15: Using Mysimba, weight loss medication, in patients who previously underwent a stomach altering operation, because of being extremely overweight, and are now regaining weight again.

Not yet recruiting
4
116
Europe
naltrexone/bupropion, Tablet, Mysimba 8 mg/90 mg prolonged-release tablets
Nederlandse Obesitas Kliniek, Goodlife
Weight regain post bariatric surgery, Weight regain after stomach altering weight loss surgery because of being overweight, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
 
 
COR-WR, NCT04587843: A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery

Active, not recruiting
4
18
Canada
Contrave 8Mg-90Mg Extended-Release Tablet, naltrexone HCl/bupropion HCl, Placebo, Inactive
St. Joseph's Healthcare Hamilton, Bausch Health, Canada Inc.
Obesity
12/23
12/23
COR-WM, NCT04589130: Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.

Active, not recruiting
4
89
Canada
Contrave 8Mg-90Mg Extended-Release Tablet, naltrexone HCl/bupropion HCl, Placebo, Inactive
St. Joseph's Healthcare Hamilton, Bausch Health, Canada Inc.
Obesity
12/23
12/23
NCT06809166: Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity

Recruiting
4
40
Canada
Contrave, Naltrexone/Bupropion-NB, Placebo, Vitamin Pill, Diet Program
The Royal's Institute of Mental Health Research, University of Ottawa, The Royal Ottawa Mental Health Centre, Bausch Health, Canada Inc., CHEO Research Institute, LEAF Weight Management Clinic
Obesity, Weight Loss, Weight Management, Dietary Intervention, Obesity/Therapy
06/25
07/25
NCT05579249: A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Completed
4
500
US
Semaglutide, Wegovy, Orlistat, Xenical, Phentermine/Topiramate, Qsymia, Naltrexone/Bupropion, Contrave, Liraglutide, Saxenda
Novo Nordisk A/S
Obesity
11/24
11/24
NCT04902625: Use of Mysimba in Patients With Weight Regain After Bariatric Surgery

Recruiting
4
116
Europe
Naltrexone-Bupropion Combination, Mysimba, Contrave
Zuyderland Medisch Centrum, Nederlandse Obesitas Kliniek
Obesity, Morbid, Bariatric Surgery Candidate, Medication Persistence
03/25
03/25
MEDFAST, NCT06845345: The Effect of Diet or Medication to Lose Weight in People with Type 2 Diabetes and Liver Scarring

Recruiting
4
70
Europe
early time restricted Mediterranean diet, early time restricted eating, mediterranean diet, intermittent fasting, dietary intervention, Mysimba, naltrexone/bupropion, pharmacological intervention
Carmen Dietvorst
Diabetes Mellitus, Type 2, Liver Fibrosis, Liver Steatoses, Hepatic Steatosis, Hepatic Fibrosis, Overweight or Obesity
07/26
03/27
STAY-LEAN, NCT06854614: Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial ( Trial)

Recruiting
4
150
US
Comprehensive weight loss, Enhanced lifestyle changes, Phentermine-Topiramate, Qsymia, Naltrexone-Bupropion Combination, Contrave, Orlistat, Xenical
The Cleveland Clinic
Obesity
12/25
12/26
NCT05919797: Weight Loss Study: Genetics and Response to Naltrexone/Bupropion

Recruiting
4
120
US
Naltrexone-Bupropion Combination, Contrave
Columbia University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Obesity
06/27
06/27
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting
4
8600
US
Naltrexone-Bupropion (NB) Combination, Placebo
Currax Pharmaceuticals
Obesity
01/29
07/29
NCT03045341: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

Completed
2/3
136
US
NB medication (Naltrexone Bupropion combination), Contrave, Behavioral Weight Loss (BWL) counseling, Placebo
Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Binge-eating Disorder, Obesity
07/21
12/22
NCT03063606: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment

Completed
2/3
31
US
Cognitive-Behavioral Therapy (CBT), NB Medication (on-going from acute treatment), Contrave
Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Binge-Eating Disorder, Obesity
12/21
12/22
NCT03047005: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy

Completed
2/3
68
US
NB medication (Naltrexone Bupropion combination), Contrave, Placebo
Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Binge-Eating Disorder, Obesity
12/21
12/22
NCT03539900: Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

Completed
2/3
89
US
Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination, Contrave, Placebo
Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Binge-Eating Disorder
04/22
03/23
NCT04599478: Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)

Recruiting
2/3
160
US
Naltrexone and Bupropion medication, Contrave, Behavioral Weight Loss, Placebo
Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Loss-of-control Eating, Obesity/Overweight
01/26
01/27
NCT04605081: Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)

Enrolling by invitation
2/3
100
US
Naltrexone and Bupropion (NB) medication, Contrave, Placebo
Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Loss-of-Control Eating, Obesity/Overweight
05/27
05/27
A-NEW, NCT04499950: Adaptive Nutrition and Exercise Weight Loss () Study

Completed
2
53
US
Contrave, Naltrexone/Bupropion, Behavioral Weight Loss
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, American Institute for Cancer Research, Breast Cancer Research Foundation, Hopkins-WellSpan Cancer Research Fund
Breast Cancer, Overweight or Obesity
01/24
01/24
NCT04553263: Relapse Prevention in Stimulant Use Disorder

Withdrawn
1
60
US
Contrave 8Mg-90Mg Extended-Release Tablet, Naltrexone HCl/Bupropion HCl 8 Mg-90 Mg, Bupropion, Wellbutrin, Zyban
University of California, Los Angeles
Stimulant Use, Relapse, Cognitive Function, ADHD
01/25
01/25
DUS, NCT06089824: Drug Utilisation of Mysimba/Contrave

Completed
N/A
43324
US
Currax Pharmaceuticals
Obesity
10/22
10/22
HOA, NCT06090461: Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

Completed
N/A
31889
US
Currax Pharmaceuticals
Obesity
12/22
12/22
NCT05756764: Anti-obesity Pharmacotherapy and Inflammation

Active, not recruiting
N/A
30
US
Semaglutide, Glucagon-like peptide-1 receptor (GLP1-R) agonist, Wegovy, Phentermine-Topiramate combination, Qsymia, Phentermine, Lomaira, Adipex-P, Tirzepatide, Mounjaro, Zepbound, GIP/GLP-1 RA, Topiramate, Topamax, Trokendi XR, Qudexy XR, Diethylpropion, Tenuate, Diethylcathinone, Naltrexone/Bupropion, Contrave, Liraglutide, Saxenda, Victoza
Louisiana State University Health Sciences Center in New Orleans, Tulane University, Pennington Biomedical Research Center, Ochsner Health System
Obesity
06/25
07/25
Cedax (ceftibuten dihydrate) / Currax
2016-003704-31: Impact on the intestinal flora during antibiotic treatment Påverkan av tarmens normalflora i samband med antibiotikabehandling

Not yet recruiting
2
120
Europe
Ciprofloxacin, Ceftibuten, Pivmecillinam, Nitrofurantoin, trimetoprim-sulfametoxazol, Coated tablet, Ciprofloxacin, Cedax, Selexid, Furadantin, Eusaprim forte
Uppsala University, Uppsala University
Impact on the intestinal microbiota during antibiotic treatment Påverkan av tarmens normalflora i samband med antibiotikabehandling, Impact on the intestinal flora during antibiotic treatment Påverkan av tarmens normalflora i samband med antibiotikabehandling, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT05554237: A Study to Learn About the Study Medicine Called CTB+AVP in Healthy Adult People.

Completed
1
42
Europe
Placebo, Placebo comparator, PF-07612577, CTB+AVP, PF-06264006, ceftibuten (CTB)
Pfizer
Healthy
06/23
06/23
NCT06593054: To Learn How Different Forms of Study Medicine Are Taken up Into the Blood and the Effect of Food on Study Medicine in Healthy Adults

Completed
1
13
Europe
Ceftibuten, Avibactam prodrug, CTB-AVP in Tablet
Pfizer
Healthy
10/24
10/24
NCT06079775: P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants

Recruiting
1
71
RoW
Xeruborbactam Oral Prodrug, QPX7831, Ceftibuten, Xeruborbactam Oral Prodrug Placebo, QPX7831 Placebo, Ceftibuten Placebo
Qpex Biopharma, Inc., Shionogi Inc., Biomedical Advanced Research and Development Authority
Bacterial Infections
08/25
10/25
NCT06665555: Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age

Completed
1
34
US
ledaborbactam etzadroxil, ceftibuten
Venatorx Pharmaceuticals, Inc., National Institute of Allergy and Infectious Diseases (NIAID)
Pharmacokinetics, Healthy Volunteers
03/25
03/25
NCT06157242: PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment

Completed
1
32
US
Xeruborbactam Oral Prodrug, QPX7831, Ceftibuten
Qpex Biopharma, Inc., Shionogi Inc., Biomedical Advanced Research and Development Authority
Bacterial Infections
03/25
03/25
VNRX-7145-106, NCT06733675: Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

Active, not recruiting
1
46
US
Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil, Esomeprazole
Venatorx Pharmaceuticals, Inc., Biomedical Advanced Research and Development Authority
Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI), FDC
08/25
09/25
Rezira (hydrocodone bitartrate/pseudoephedrine) / Currax
No trials found

Download Options